IBA Executive and Leadership Team

Ikram Syed, the Chief Executive Officer at IBA, directs the company's overall strategy and global operations. This leadership role involves guiding IBA's mission to design and produce innovative particle accelerator solutions for medical and industrial sectors. Syed oversees the development of equipment crucial for cancer diagnosis and treatment, alongside industrial applications like medical device sterilization. The focus remains on improving health outcomes by supporting hospitals worldwide with advanced technology maintenance and upgrades. This executive ensures the company's continued impact in protecting, enhancing, and saving lives through technological advancement. Ikram Syed drives the strategic vision that positions IBA as a global leader in its specialized field, fostering innovation and operational excellence across all departments. The Chief Executive Officer's purview encompasses all facets of the business, from research and development to market expansion and client relations, ensuring sustained growth and industry leadership.

Irwin Thomashow, the Chief Financial Officer at IBA, manages the company's financial health and strategic fiscal planning. This executive oversees all financial operations, including budgeting, forecasting, and investment strategies, ensuring robust financial performance. Thomashow's responsibilities extend to managing capital allocation for research and development initiatives, particularly for advanced cancer treatment and diagnosis equipment. The Chief Financial Officer plays a critical part in securing funding for global expansion and maintaining strong relationships with financial institutions. Irwin Thomashow ensures compliance with all financial regulations and drives initiatives to optimize profitability and shareholder value. This leadership position is vital for sustaining IBA's capacity to provide, maintain, and upgrade life-saving technology for hospitals worldwide. The financial strategy executed by Thomashow directly supports the company's mission to enhance global health outcomes through technological innovation and operational efficiency.

Pr Costa, the President at IBA, drives the company's overarching operational execution and strategic market positioning. This executive leads the global business development efforts, focusing on expanding IBA's reach in both medical and industrial applications of particle accelerator technology. Costa oversees the integration of new technologies and ensures operational efficiency across manufacturing and service departments. The President's role involves fostering key partnerships with healthcare providers and industrial clients to deliver cutting-edge solutions for cancer treatment, diagnosis, and sterilization processes. Pr Costa is instrumental in translating the company's innovative designs into tangible market successes, supporting hospitals globally with essential technological advancements. This leadership ensures IBA's continued commitment to protecting, enhancing, and saving lives through superior product delivery and client support. Costa's strategic direction underpins the company's mission to be a leader in advanced technology solutions.

Mary Klein, the President, Iba Proton Therapy (North America) at IBA, directs the strategic growth and operational oversight for proton therapy solutions across the North American region. This executive focuses on expanding access to advanced cancer treatment technologies, ensuring IBA's market leadership in this critical medical sector. Klein manages relationships with key healthcare institutions throughout North America, facilitating the deployment and integration of proton therapy systems. The President's responsibilities include driving sales, overseeing project implementations, and ensuring comprehensive client support for installed equipment. Mary Klein's leadership ensures that hospitals in North America receive state-of-the-art technology designed to protect, enhance, and save lives. This role is pivotal in advancing IBA's mission to improve health outcomes through innovative medical solutions, specifically targeting the unique demands and opportunities within the North American market.